Benzatropine

Benzatropine
Clinical data
Trade namesCogentin, others
Other namesbenzatropine (BAN UK), benztropine (USAN US)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B2
Routes of
administration		By mouth, intramuscular, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismLiver
Elimination half-life12–24 hours
ExcretionKidney
Identifiers
  • (3-endo)-3-(Diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H25NO
Molar mass307.437 g·mol−1
3D model (JSmol)
  • CN4[C@@H]1CC[C@H]4C[C@H](C1)OC(c2ccccc2)c3ccccc3
  • InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20+ checkY
  • Key:GIJXKZJWITVLHI-PMOLBWCYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Benzatropine (INN[2]), known as benztropine in the United States and Japan,[3] is a medication used to treat movement disorders like parkinsonism and dystonia, as well as extrapyramidal side effects of antipsychotics, including akathisia.[4] It is not useful for tardive dyskinesia.[4] It is taken by mouth or by injection into a vein or muscle.[4] Benefits are seen within two hours and last for up to ten hours.[5][6]

Common side effects include dry mouth, blurry vision, nausea, and constipation.[4] Serious side effect may include urinary retention, hallucinations, hyperthermia, and poor coordination.[4] It is unclear if use during pregnancy or breastfeeding is safe.[7] Benzatropine is an anticholinergic which works by blocking the activity of the muscarinic acetylcholine receptor.[4]

Benzatropine was approved for medical use in the United States in 1954.[4] It is available as a generic medication.[4] In 2020, it was the 229th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[8][9] It is sold under the brand name Cogentin among others.[4]

  1. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 6 July 2023. Retrieved 30 March 2024.
  2. ^ World Health Organization (December 1959). "International Non-Proprietary Names for Pharmaceutical Preparations). Recommended International Non-Proprietary Names (Rec. I.N.N.): List 3º" (PDF). WHO Chronicle. 13 (12): 464. Archived (PDF) from the original on 28 August 2021. Retrieved 1 December 2020.
  3. ^ World Health Organization. "INN: Benzatropine". WHO MedNet. Retrieved 1 December 2020.[permanent dead link]
  4. ^ a b c d e f g h i "Benztropine Mesylate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 June 2019. Retrieved 9 April 2019.
  5. ^ Pagliaro LA, Pagliaro AM (1999). PNDR, Psychologists' Neuropsychotropic Drug Reference. Psychology Press. p. 47. ISBN 9780876309568.
  6. ^ Aschenbrenner DS, Venable SJ (2009). Drug Therapy in Nursing. Lippincott Williams & Wilkins. p. 197. ISBN 9780781765879.
  7. ^ "Benztropine (Cogentin) Use During Pregnancy". Drugs.com. Archived from the original on 6 June 2019. Retrieved 9 April 2019.
  8. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 7 October 2022.
  9. ^ "Benztropine - Drug Usage Statistics". ClinCalc. Archived from the original on 12 May 2023. Retrieved 7 October 2022.